These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 15844174)

  • 1. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
    Omuro AM; Kris MG; Miller VA; Franceschi E; Shah N; Milton DT; Abrey LE
    Cancer; 2005 Jun; 103(11):2344-8. PubMed ID: 15844174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
    Namba Y; Kijima T; Yokota S; Niinaka M; Kawamura S; Iwasaki T; Takeda Y; Kimura H; Okada T; Yamaguchi T; Nakagawa M; Okumura Y; Maeda H; Ito M
    Clin Lung Cancer; 2004 Sep; 6(2):123-8. PubMed ID: 15476598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
    Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
    Yokouchi H; Yamazaki K; Kinoshita I; Konishi J; Asahina H; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
    BMC Cancer; 2007 Mar; 7():51. PubMed ID: 17374153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib.
    Chen MJ; Zhong W; Zhang L; Zhao J; Li LY; Wang MZ
    Chin Med J (Engl); 2013 Jun; 126(12):2235-41. PubMed ID: 23786931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.
    Nishino K; Imamura F; Morita S; Mori M; Komuta K; Kijima T; Namba Y; Kumagai T; Yamamoto S; Tachibana I; Nakazawa Y; Uchida J; Minami S; Takahashi R; Yano Y; Okuyama T; Kumanogoh A
    Lung Cancer; 2013 Nov; 82(2):299-304. PubMed ID: 24018023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A; Mittal N
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
    Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
    Chiu CH; Tsai CM; Chen YM; Chiang SC; Liou JL; Perng RP
    Lung Cancer; 2005 Jan; 47(1):129-38. PubMed ID: 15603863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.
    Segawa Y; Hotta K; Umemura S; Fujiwara Y; Shinkai T; Ueoka H; Takigawa N; Tabata M; Kiura K; Tanimoto M
    Cancer; 2006 Oct; 107(8):1866-72. PubMed ID: 16967452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
    Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S
    Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis.
    Ceresoli GL; Reni M; Chiesa G; Carretta A; Schipani S; Passoni P; Bolognesi A; Zannini P; Villa E
    Cancer; 2002 Aug; 95(3):605-12. PubMed ID: 12209754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
    van Puijenbroek R; Bosquée L; Meert AP; Schallier D; Goeminne JC; Tits G; Collard P; Nackaerts K; Canon JL; Duplaquet F; Galdermans D; Germonpré P; Azerad MA; Vandenhoven G; De Greve J; Vansteenkiste J
    Eur Respir J; 2007 Jan; 29(1):128-33. PubMed ID: 17005582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
    Reck M; Gatzemeier U
    Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.